KR100984184B1 - 알긴산 스폰지 및 그의 제조방법 - Google Patents
알긴산 스폰지 및 그의 제조방법 Download PDFInfo
- Publication number
- KR100984184B1 KR100984184B1 KR1020030016849A KR20030016849A KR100984184B1 KR 100984184 B1 KR100984184 B1 KR 100984184B1 KR 1020030016849 A KR1020030016849 A KR 1020030016849A KR 20030016849 A KR20030016849 A KR 20030016849A KR 100984184 B1 KR100984184 B1 KR 100984184B1
- Authority
- KR
- South Korea
- Prior art keywords
- alginic acid
- sponge
- alginate
- acid sponge
- aqueous solution
- Prior art date
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 117
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 117
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229940072056 alginate Drugs 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title description 2
- 229960001126 alginic acid Drugs 0.000 claims abstract description 93
- 239000000783 alginic acid Substances 0.000 claims abstract description 93
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 91
- 239000007864 aqueous solution Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 238000010521 absorption reaction Methods 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- 238000000465 moulding Methods 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 238000005452 bending Methods 0.000 claims abstract description 11
- 238000004132 cross linking Methods 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 11
- 235000010413 sodium alginate Nutrition 0.000 claims description 11
- 239000000661 sodium alginate Substances 0.000 claims description 11
- 229940005550 sodium alginate Drugs 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- -1 alginic acid alkali metal salt Chemical class 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 235000010407 ammonium alginate Nutrition 0.000 claims description 3
- 239000000728 ammonium alginate Substances 0.000 claims description 3
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 235000010408 potassium alginate Nutrition 0.000 claims description 3
- 239000000737 potassium alginate Substances 0.000 claims description 3
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 108010081589 Becaplermin Proteins 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000002174 Styrene-butadiene Substances 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 238000004512 die casting Methods 0.000 claims description 2
- 230000000925 erythroid effect Effects 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000011115 styrene butadiene Substances 0.000 claims description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000704 physical effect Effects 0.000 abstract description 6
- 239000011148 porous material Substances 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 235000010410 calcium alginate Nutrition 0.000 description 4
- 239000000648 calcium alginate Substances 0.000 description 4
- 229960002681 calcium alginate Drugs 0.000 description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Abstract
Description
구분 | 실시예 1 | 실시예 2 | 실시예 3 | 비교예 1 |
유연성 (°) | 150 | 140 | 145 | 70 |
기공의 평균 크기 (g/㎤) | 0.0377 | 0.0341 | 0.0384 | 0.0046 |
흡수율 (%) | 306 | 268 | 289 | × |
Claims (9)
- 최대 굽힘 각도(유연성)가 90 ° 이상이고, 겉보기 밀도(구조치밀성)가 0.006~0.1 g/㎤이고, 식염수 흡수율이 150~700 %인 알긴산 스폰지.
- 알긴산 스폰지의 제조방법에 있어서,a) 알긴산 수용액을 성형틀 투입법, 코팅법, 다이케스팅법, 또는 압출법으로 성형한 후에, 성형된 알긴산 수용액을 동결건조하여 알긴산 스폰지 중간재를 제조하는 단계; 및b) 상기 a)단계의 알긴산 스폰지 중간재를 가교제 수용액에 침지하여 가교시킨 후, 세정 및 건조하여 알긴산 스폰지를 제조하는 단계를 포함하고, 알긴산 스폰지의 성형과 가교를 별도의 단계로 분리하여 수행하며, 성형 및 동결건조를 수행한 후에 가교 단계를 수행하는 것을 특징으로 하는 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 a)단계의 알긴산 수용액이 알긴산 나트륨염, 알긴산 칼륨염, 및 알긴산 암모늄염으로 이루어지는 군으로부터 선택되는 알긴산 또는 알긴산 알칼리 금속염을 0.5 내지 30 중량%의 농도로 함유하는 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 a)단계의 알긴산 수용액이 알칼리 금속염, 폴리에틸렌옥사이드, 폴리비닐알콜, 카르복시메틸셀룰로오스, 카르복실레이티드 스티렌 부티다엔 라텍스, 폴리 비닐피롤리돈, 코코넛 오일, 글리세린, 및 계면활성제로 이루어지는 군으로부터 1 종 이상 선택되는 물질을 추가로 포함하는 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 a)단계의 알긴산 수용액이 피브로넥틴, 비트로넥틴, 산성 섬유아세포 성장인자 FGF, 염기성 FGF, KGF, VEGF, EGF, PDFG-AA, PDGF-AB, PDGF-BB, TGF-α, TGF-β, IGF, TNF, GM-CSF, NGF, 헤파린결합 EGF, 인터페론, 적혈구 조혈인자, 1L-1(인터루킨-1), IL-2, IL-6, IL-8, 및 조직활성화 펩티드로 이루어지는 군으로부터 1 종 이상 선택되는 생체 활성 인자를 추가로 포함하는 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 b)단계의 가교제 수용액에 함유되는 가교제가 2가 금속염 또는 공유결합능을 가지는 유기계 가교제인 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 b)단계의 가교제 수용액이 생체 활성 인자, 수용성 키토산, 히알루론산, 펙틴, 및 젤라틴으로 이루어지는 군으로부터 1 종 이상 선택되는 물질을 추가로 포함하는 알긴산 스폰지의 제조방법.
- 제2항에 있어서,상기 알긴산 스폰지의 최대 굽힘 각도(유연성)가 90 ° 이상이고, 겉보기 밀도(구조치밀성)가 0.006~0.1 g/㎤이고, 식염수 흡수율이 150~700 %인 알긴산 스폰지의 제조방법.
- 제1항에 있어서,최대 굽힘 각도(유연성)가 145 ° 이상이고, 겉보기 밀도(구조치밀성)가 0.0341~0.1 g/㎤이고, 식염수 흡수율이 268~700%인 알긴산 스폰지.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030016849A KR100984184B1 (ko) | 2003-03-18 | 2003-03-18 | 알긴산 스폰지 및 그의 제조방법 |
US10/549,002 US20060240080A1 (en) | 2003-03-18 | 2004-03-17 | Alginate sponge and preparation method thereof |
PCT/KR2004/000570 WO2004082594A2 (en) | 2003-03-18 | 2004-03-17 | Alginate sponge and preparation method thereof |
TW093107314A TWI279404B (en) | 2003-03-18 | 2004-03-18 | Alginate sponge and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030016849A KR100984184B1 (ko) | 2003-03-18 | 2003-03-18 | 알긴산 스폰지 및 그의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040082172A KR20040082172A (ko) | 2004-09-24 |
KR100984184B1 true KR100984184B1 (ko) | 2010-09-28 |
Family
ID=33028825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030016849A KR100984184B1 (ko) | 2003-03-18 | 2003-03-18 | 알긴산 스폰지 및 그의 제조방법 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060240080A1 (ko) |
KR (1) | KR100984184B1 (ko) |
TW (1) | TWI279404B (ko) |
WO (1) | WO2004082594A2 (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100644369B1 (ko) * | 2004-10-25 | 2006-11-10 | 한국화학연구원 | 피부드레싱용 키토산-젤라틴-알진 스폰지 및 이의 제조방법 |
EP1988942B1 (en) * | 2006-03-01 | 2011-07-27 | FMC Biopolymer AS | Gelled composite |
KR100740169B1 (ko) * | 2006-06-28 | 2007-07-16 | 학교법인 포항공과대학교 | 세포를 포함하는 알긴산 마이크로 섬유 지지체 및 그제작방법 |
IL187707A0 (en) * | 2007-11-27 | 2008-11-03 | Univ Ben Gurion | Alginate scaffold in hepatectomy |
CN101249275B (zh) * | 2008-01-10 | 2011-06-29 | 中国人民解放军第二军医大学 | 一种可隔离海水的创面敷料及其制备方法 |
CN102078636A (zh) * | 2011-01-07 | 2011-06-01 | 中山大学孙逸仙纪念医院 | 含重组人表皮生长因子的水凝胶敷料及其制备方法与应用 |
WO2014102801A1 (en) | 2012-12-30 | 2014-07-03 | Hadasit Medical Research Services And Development Ltd. | Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent |
KR101694121B1 (ko) * | 2014-10-28 | 2017-01-10 | (주)헵틸와이 | 이중 가교구조의 생체친화형 다공성 시트 및 그 제조방법 |
RU2018112431A (ru) * | 2015-09-07 | 2019-10-09 | Мотида Фармасьютикал Ко., Лтд. | Лиофилизированный препарат альгиновой кислоты |
GB2553260B (en) * | 2016-05-17 | 2021-06-16 | Datt Mediproducts Ltd | A ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix and a method of manufacturing thereof |
CN107296978A (zh) * | 2017-08-04 | 2017-10-27 | 北京化工大学常州先进材料研究院 | 一种生物体海绵状医用止血材料 |
CN108904874A (zh) * | 2018-06-28 | 2018-11-30 | 戴建英 | 具有促进创面湿性愈合作用的膜片状医用凝胶、制造方法及其应用 |
CN112076343A (zh) * | 2020-08-14 | 2020-12-15 | 中国人民解放军南部战区总医院 | 一种海藻酸盐-羧甲基纤维素凝胶海绵及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1378931A (en) * | 1972-01-03 | 1974-12-27 | Freeze Dry Products | Alginate sponge and process therefor |
GB9209327D0 (en) * | 1992-04-30 | 1992-06-17 | Johnson & Johnson Medical | Freeze-dried pad |
IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
GB2318577B (en) * | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
US5718916A (en) * | 1997-02-03 | 1998-02-17 | Scherr; George H. | Alginate foam products |
US6696077B2 (en) * | 2001-07-26 | 2004-02-24 | George H. Scherr | Silver alginate foam compositions |
-
2003
- 2003-03-18 KR KR1020030016849A patent/KR100984184B1/ko active IP Right Grant
-
2004
- 2004-03-17 WO PCT/KR2004/000570 patent/WO2004082594A2/en active Application Filing
- 2004-03-17 US US10/549,002 patent/US20060240080A1/en not_active Abandoned
- 2004-03-18 TW TW093107314A patent/TWI279404B/zh active
Non-Patent Citations (1)
Title |
---|
논문 1: Biomaterials |
Also Published As
Publication number | Publication date |
---|---|
WO2004082594A3 (en) | 2004-12-16 |
TWI279404B (en) | 2007-04-21 |
US20060240080A1 (en) | 2006-10-26 |
WO2004082594A2 (en) | 2004-09-30 |
KR20040082172A (ko) | 2004-09-24 |
TW200424216A (en) | 2004-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kanimozhi et al. | Development of biomimetic hybrid porous scaffold of chitosan/polyvinyl alcohol/carboxymethyl cellulose by freeze-dried and salt leached technique | |
KR100984184B1 (ko) | 알긴산 스폰지 및 그의 제조방법 | |
JP4667486B2 (ja) | 水溶性エラスチンの架橋剤 | |
CN110152051B (zh) | 一种吸水烧创伤抗菌敷料及其制备方法和用途 | |
CN108912352A (zh) | 一种抗菌粘附可注射水凝胶敷料及其制备方法和应用 | |
CA2861027A1 (en) | Collagen structure, and method for producing collagen structure | |
Song et al. | Kaolin-loaded carboxymethyl chitosan/sodium alginate composite sponges for rapid hemostasis | |
CN113769156A (zh) | 兼具止血和创面修复的杂化纤维海绵及其制备方法 | |
CN114031807A (zh) | 一种用于组织创伤愈合修复的纤维素壳聚糖单宁酸铜复合凝胶海绵及其制备方法 | |
ITPD980037A1 (it) | Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti | |
ES2366481T3 (es) | Cuerpo moldeado para el tratamiento de heridas. | |
CN113968984A (zh) | 一种安全长效的多功能伤口敷料的制备方法 | |
KR100440239B1 (ko) | 상처 치료용 수화겔의 제조방법 | |
Feng et al. | A hemostatic keratin/alginate hydrogel scaffold with methylene blue mediated antimicrobial photodynamic therapy | |
KR102302405B1 (ko) | 마이크로-비드 및 그 제조방법, 이를 포함하는 지혈 드레싱의 제조방법 | |
Song et al. | Electrospinning/3D printing drug-loaded antibacterial polycaprolactone nanofiber/sodium alginate-gelatin hydrogel bilayer scaffold for skin wound repair | |
CN107216496A (zh) | 一种可控氨基含量的壳聚糖材料及其制备方法 | |
CN108452366B (zh) | 一种鳕鱼皮明胶复合止血敷料及其制备方法 | |
KR100608192B1 (ko) | 창상 피복재 및 조직공학 구조체용 중화 키토산 스폰지제조방법 및 이에 의해 제조된 중화 키토산 스폰지 | |
CN112979999B (zh) | 生物大分子及改性埃洛石复合水凝胶及其制备和应用 | |
CN115177778A (zh) | 一种复合型伤口敷料、制备方法及应用 | |
KR100987818B1 (ko) | 수용성 키토산으로 코팅된 알긴산 스폰지 및 이의 제조방법 | |
KR100993006B1 (ko) | 키토산으로 코팅된 알긴산 스폰지 및 이의 제조방법 | |
JPH06245988A (ja) | 創傷被覆材 | |
KR101797465B1 (ko) | 물성이 개선된 알긴산 폼 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130822 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140820 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150819 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160822 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170828 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180823 Year of fee payment: 9 |